Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.
Update on the restructuring of the AB Science clinical development department in 2018
19/12/2018 – AB Science provides the main achievements of this restructuring.
Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment
22/10/2018 – Final results will be available in 2019.
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis
08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.
First half of 2018 revenues
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.
Results of the Combined General Shareholders’ Meeting held on June 29 2018
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.
Combined General Shareholders’ Meeting held on June 29, 2018
03/07/2018 – Presentation of the current situation and future prospects.
Positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer
19/06/2018 – AB Science expects study to be completed in 2019.